CCT6A and autoimmune disease: Accordingly, CCT6A may be considered a novel ligand for γδ T cells in human autoimmune diseases, and to explain its presence in patient plasma and on cell membrane surfaces, it has been suggested that CCT6A in the plasma membrane may be recognized by γδ T cells, leading to tissue damage, which, in turn, can release CCT6A into the plasma and sustain the activation of γδ T cells [103].